CNClinicalTrials.govClinical trialPhase 3Recruiting
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Official record
- Identifier
NCT07562022- Recruiting locations
country
China- Interventions studied
- SCTB35 injectionRituximabLenalidomide
- Lead sponsor
- Sinocelltech Ltd.
- Target enrolment
- 93 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Status
- Recruiting
- First posted
- May 1, 2026
- Last updated on the registry
- Aug 13, 2026
- Age
- 18 Years – 80 Years
- Sex
- ALL
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * Age 18-80 years old * Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria * Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy * Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion * A measurable or evaluable disease at the time of enrolment * ECOG PS 0-2 * Adequate organ function and bone marrow function * Expected survival ≥ 6 months Exclusion Criteria: * Documented refractoriness to lenalidomide. * Have lenalidomide exposure within 12 months prior to randomization
- Indexed under
- Lymphoma